1
|
Grewal H, Kedar R, Dhillon G, Sidhu G, Kashyap R, Sailagundala K. SpaceOAR hydrogel complications in prostate cancer. Br J Radiol 2023; 96:20230717. [PMID: 37750832 PMCID: PMC10646634 DOI: 10.1259/bjr.20230717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Revised: 09/11/2023] [Accepted: 09/12/2023] [Indexed: 09/27/2023] Open
Abstract
SpaceOAR hydrogel, a novel biodegradable spacer, is increasingly used in managing prostate cancer patients undergoing radiation therapy to minimize rectal radiation dose and associated complications. However, its use has raised new concerns regarding its potential complications and impact on subsequent imaging interpretation. This article provides a pictorial review of the imaging complications of using SpaceOAR hydrogel in prostate cancer patients. We present multiple examples demonstrating the types of complications that can occur, potential underlying mechanisms, and their impact on patient outcomes and imaging interpretation. This review aims to provide radiologists and oncologists with an updated understanding of these complications, guiding better patient management and interpretation of imaging studies.
Collapse
Affiliation(s)
- Harpreet Grewal
- Department of Radiology, Sacred Heart Hospital, Radiology Associates of Florida, Pensacola, United States
| | - Rajendra Kedar
- Department of Radiology, Tampa General Hospital, University of South Florida Morsani College of Medicine, Radiology Associates of Florida, Tampa, United States
| | - Gagandeep Dhillon
- Department of Internal Medicine, University of Maryland Baltimore Washington Medical Center, Glen Burnie, United States
| | - Gurmanpreet Sidhu
- Department of Pathology, Government Medical College, Patiala, Punjab, India
| | | | - Kiran Sailagundala
- Department of Radiology, Sacred Heart Hospital, Radiology Associates of Florida, Pensacola, United States
| |
Collapse
|
2
|
Wang Z, Wang J, Yao Y, Wang F, Fan Q, Zhao R. Low-activity 125I implantation into VX 2 tumor rabbits and quantitative evaluation of the precise therapeutic effect. Exp Ther Med 2021; 22:1438. [PMID: 34721680 PMCID: PMC8549107 DOI: 10.3892/etm.2021.10873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Accepted: 08/18/2021] [Indexed: 01/09/2023] Open
Abstract
There is still controversy about quantitatively evaluating the therapeutic effect of radioactive low-activity iodine-125 seeds (125I seeds). In the present study, a paired VX2 tumor model in a rabbit hind leg muscle was established, which is virus-induced anaplastic squamous cell carcinoma characterized by hypervascularity, rapid growth and easy propagation in the skeletal muscle. 125I seeds with 0.4 and 0.7 mCi activity were implanted into the left and right legs, respectively, using a radiation treatment planning system under positron emission tomography (PET)/computed tomography (CT) guidance. PET/CT scans and hematoxylin and eosin staining were observed at 72 h and 2 and 4 weeks after implantation to assess the therapeutic effect. The results showed that the average tumor length and standard uptake value (SUV) decreased over time, and both 125I seed groups achieved therapeutic effects at 4 weeks post-implantation. Quantitative evaluation of tumor inhibition rate, SUV variation and tumor marker ratio (Bcl-2/Bax) suggested that 0.7 mCi 125I seeds were more suitable than 0.4 mCi seeds in a clinical setting.
Collapse
Affiliation(s)
- Zheng Wang
- Department of Nuclear Medicine, Jincheng Anthracitic Coal Mining Group General Hospital, Jincheng, Shanxi 048006, P.R. China
| | - Juan Wang
- Department of Nuclear Medicine, Jincheng Anthracitic Coal Mining Group General Hospital, Jincheng, Shanxi 048006, P.R. China
| | - Yongyi Yao
- Department of Nuclear Medicine, Jincheng Anthracitic Coal Mining Group General Hospital, Jincheng, Shanxi 048006, P.R. China
| | - Feng Wang
- Department of Nuclear Medicine, Jincheng Anthracitic Coal Mining Group General Hospital, Jincheng, Shanxi 048006, P.R. China
| | - Qiang Fan
- Department of Nuclear Medicine, Jincheng Anthracitic Coal Mining Group General Hospital, Jincheng, Shanxi 048006, P.R. China
| | - Ruifeng Zhao
- Department of Nuclear Medicine, Jincheng Anthracitic Coal Mining Group General Hospital, Jincheng, Shanxi 048006, P.R. China,Correspondence to: Dr Ruifeng Zhao, Department of Nuclear Medicine, Jincheng Anthracitic Coal Mining Group General Hospital, 227 Provincial Road, Beishidian, Jincheng, Shanxi 048006, P.R. China
| |
Collapse
|
3
|
|
4
|
Merrell KW, Davis BJ, Goulet CC, Furutani KM, Mynderse LA, Harmsen WS, Wilson TM, McLaren RH, Deufel CL, Birckhead BJ, Funk RK, McMenomy BP, Stish BJ, Choo CR. Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds. Brachytherapy 2019; 18:306-312. [PMID: 30853392 DOI: 10.1016/j.brachy.2019.01.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Revised: 01/10/2019] [Accepted: 01/18/2019] [Indexed: 12/25/2022]
Abstract
PURPOSE Pulmonary seed emboli to the chest may occur after permanent prostate brachytherapy (PPB). The purpose of this study is to analyze factors associated with seed migration to the chest in a large series of PPB patients from a single institution undergoing implant with either loose seeds (LS), mixed loose and stranded seeds (MS), or exclusively stranded seeds in an absorbable vicryl suture (VS). METHODS AND MATERIALS Between May 1998 and July 2015, a total of 1000 consecutive PPB patients with postoperative diagnostic chest x-rays at 4 months after implant were analyzed for seed migration. Patients were grouped based on seed implant technique: LS = 391 (39.1%), MS = 43 (4.3%), or VS = 566 (56.6%). Univariate and multivariate analysis were performed using Cox proportional hazards regression models to determine predictors of seed migration. RESULTS Overall, 18.8% of patients experienced seed migration to the chest. The incidence of seed migration per patient was 45.5%, 11.6%, and 0.9% (p < 0.0001), for patients receiving LS, MS, or VS PPB, respectively. The right and left lower lobes were the most frequent sites of pulmonary seed migration. On multivariable analysis, planimetry volume (p = 0.0002; HR = 0.7 per 10 cc [0.6-0.8]), number of seeds implanted (p < 0.0001, HR = 2.4 per 25 seeds [1.7-3.4]), LS implant (p < 0.0001, HR = 15.9 [5.9-42.1]), and MS implant (p = 0.001, HR = 7.9 [2.3-28.1]) were associated with seed migration to the chest. CONCLUSIONS In this large series, significantly higher rates of seed migration to the chest are observed in implants using any LS with observed hazard ratios of 15.9 and 7.9 for LS and MS respectively, as compared with implants using solely stranded seeds.
Collapse
Affiliation(s)
| | - Brian J Davis
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN.
| | | | | | | | - W Scott Harmsen
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN
| | | | | | | | - Brandon J Birckhead
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI
| | - Ryan K Funk
- Department of Radiation Oncology, Minnesota Oncology, Minneapolis, MN
| | | | - Bradley J Stish
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| | - C Richard Choo
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN
| |
Collapse
|
5
|
Nakano M, Yorozu A, Saito S, Sugawara A, Maruo S, Kojima S, Kikuchi T, Fukushima M, Dokiya T, Yamanaka H. Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study. Radiat Oncol 2015; 10:228. [PMID: 26577301 PMCID: PMC4650265 DOI: 10.1186/s13014-015-0532-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2015] [Accepted: 10/28/2015] [Indexed: 11/10/2022] Open
Abstract
Background The incidence and associated factors of loose seed migration were investigated in cohort 1 of the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS). Methods The study subjects were 2160 patients, consisting of 1641 patients who underwent permanent iodine-125 seed implantation (PI) and 519 patients who underwent PI combined with external beam radiation therapy (PI + EBRT). The presence or absence of seed migration to the chest and abdominal/pelvic region was determined. Results Seed migration was observed in 22.7 % of PI group patients and 18.1 % of PI + EBRT group patients (p = 0.0276). Migration to the lungs and abdominal/pelvic region was observed in 14.6 % and 11.1 % of the patients in the PI group, and 11.2 % and 8.5 % of the patients in the PI + EBRT group, respectively. In the PI group, the number of implanted seeds was associated with the seed migration incidence. Neither the PI nor the PI + EBRT group showed any difference in the volume of the prostate receiving 100 % of the prescribed dose (V100 [%]) or the minimal dose received by 90 % of the prostate volume (D90 [Gy]) between the patients with and without seed migration. Conclusions This prospective cohort study investigating the largest number of past cases showed no difference in D90 (Gy) or V100 (%) between seed migration or the absence thereof in both the PI group and PI + EBRT group. Trial registration ClinicalTrials.gov: NCT00534196
Collapse
Affiliation(s)
- Masahiro Nakano
- Department of Urology, Gifu University Graduate School of Medicine, 1-1Yanagito, Gifu-shi, Gifu, 501-1194, Japan.
| | - Atsunori Yorozu
- Department of Radiation Oncology, National Hospital Organization, Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
| | - Shiro Saito
- Department of Urology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
| | - Akitomo Sugawara
- Department of Radiation Oncology, Tokai University, Hachioji Hospital, 1838 Ishikawa-machi, Hachioji-shi, Tokyo, 192-0032, Japan.
| | - Shinichiroh Maruo
- Translational Research Informatics center, 1-5-4 Minatojima-minamimachi Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
| | - Shinsuke Kojima
- Translational Research Informatics center, 1-5-4 Minatojima-minamimachi Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
| | - Takashi Kikuchi
- Translational Research Informatics center, 1-5-4 Minatojima-minamimachi Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
| | - Masanori Fukushima
- Translational Research Informatics center, 1-5-4 Minatojima-minamimachi Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
| | - Takushi Dokiya
- Department of Radiology, Kyoundo Hospital, 1-8 Kandasurugadai, Chiyoda-ku, Tokyo, 101-0062, Japan.
| | - Hidetoshi Yamanaka
- Institute of Preventive Medicine, Kurosawa Hospital, 187 Yanakamachi, Takasaki-shi, Gunma, 370-1203, Japan.
| |
Collapse
|